Economic Forecast

Canada’s participation in the world economy has given rise to a number of issues that have impacted the speed and nature of growth across the country.  How we deal with current challenges will affect growth prospects in the longer term.  This presentation will seek to identify where Canada is today, what structural problems exist that will inhibit growth, possible solutions to remedy such problems and an overview of where the economy is heading. The impact that these uncertain economic times will have on the Canadian worker (and their pensions) will also be explored.

Speaker: Dr. Jamal Hejazi

Dr. Jamal Hejazi is a senior member of the Gowlings Transfer Pricing and Competent Authority team as well as the Firm's China Group. Working in conjunction with the Firm's National Tax Practice Group, Jamal helps organizations optimize their global tax position and reduce exposure to unfavorable audit assessments through proper tax planning and implementation strategies. He has been involved in work for a number of industries including automotive, pharmaceutical, energy, computer software, gaming, manufacturing and services. He also specializes in intangible valuation and has done work for both the technology and biochemical sectors.

Prior to joining Gowlings, Jamal was a senior transfer pricing economist with the Canada Revenue Agency, where he participated in the resolution of a number of transfer pricing issues, including the relief of double taxation on Canadian corporations. He was instrumental in the negotiation of Advanced Pricing Agreements between Canada and foreign tax authorities.

Jamal has also held a faculty position at the University of Windsor, and was a lecturer at both Carleton University and the University of Phoenix. He is currently on faculty at York University's Asian Business and Management program as well as the executive MBA program at the Telfer School of Management.

_____________________________________________________________________________

Understanding Biological Drugs

This presentation will provide an image of the average cost of biological drugs in Canada as well as a forecast of what is to come in future years. From the moment the cost of a drug is approved by the PMPRB and for the years following its introduction in the market place. In addition to this, our guest speaker will expand on the factors driving the cost of these drugs as well as their impact on human life. 

Speaker: Michelle Boudreau

Michelle is the Vice President, Private Markets, Canada’s Research-Based Pharmaceutical Companies (Rx&D). Before joining Rx&D in October 2013, Michelle was the Executive Director of the Patented Medicine Prices Review Board (PMPRB).

Michelle has proven expertise in corporate leadership and program delivery. She has over fifteen years’ experience in the development of government policy. Her areas of expertise include intellectual property policy and health products regulation.  She served in several senior executive roles with the Government of Canada.

Michelle has a Bachelor of Science in Pharmacy from Dalhousie University and a Bachelor of Laws from University of Ottawa.  Michelle lives in Ottawa where she enjoys its outdoor activities, including cycling, running and cross-country skiing.

               To Register on-line click on the "Register Now" button above

or
>>OPEN<< the pdf registration form